Literature DB >> 25646432

Macrophages eat cancer cells using their own calreticulin as a guide: roles of TLR and Btk.

Mingye Feng1, James Y Chen1, Rachel Weissman-Tsukamoto1, Jens-Peter Volkmer1, Po Yi Ho1, Kelly M McKenna1, Samuel Cheshier2, Michael Zhang2, Nan Guo1, Phung Gip1, Siddhartha S Mitra2, Irving L Weissman3.   

Abstract

Macrophage-mediated programmed cell removal (PrCR) is an important mechanism of eliminating diseased and damaged cells before programmed cell death. The induction of PrCR by eat-me signals on tumor cells is countered by don't-eat-me signals such as CD47, which binds macrophage signal-regulatory protein α to inhibit phagocytosis. Blockade of CD47 on tumor cells leads to phagocytosis by macrophages. Here we demonstrate that the activation of Toll-like receptor (TLR) signaling pathways in macrophages synergizes with blocking CD47 on tumor cells to enhance PrCR. Bruton's tyrosine kinase (Btk) mediates TLR signaling in macrophages. Calreticulin, previously shown to be an eat-me signal on cancer cells, is activated in macrophages for secretion and cell-surface exposure by TLR and Btk to target cancer cells for phagocytosis, even if the cancer cells themselves do not express calreticulin.

Entities:  

Keywords:  Bruton's tyrosine kinase; Toll-like receptor; immunosurveillance; programmed cell removal; “eat me” signal

Mesh:

Substances:

Year:  2015        PMID: 25646432      PMCID: PMC4343163          DOI: 10.1073/pnas.1424907112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  45 in total

1.  Defective Fc-, CR1- and CR3-mediated monocyte phagocytosis and chemotaxis in common variable immunodeficiency and X-linked agammaglobulinemia patients.

Authors:  A L Amoras; H Kanegane; T Miyawaki; M M Vilela
Journal:  J Investig Allergol Clin Immunol       Date:  2003       Impact factor: 4.333

2.  Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells.

Authors:  D Kim; J Wang; S B Willingham; R Martin; G Wernig; I L Weissman
Journal:  Leukemia       Date:  2012-05-30       Impact factor: 11.528

Review 3.  TLR signaling.

Authors:  T Kawai; S Akira
Journal:  Cell Death Differ       Date:  2006-05       Impact factor: 15.828

4.  CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis.

Authors:  Siddhartha Jaiswal; Catriona H M Jamieson; Wendy W Pang; Christopher Y Park; Mark P Chao; Ravindra Majeti; David Traver; Nico van Rooijen; Irving L Weissman
Journal:  Cell       Date:  2009-07-23       Impact factor: 41.582

5.  Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy.

Authors:  Mark P Chao; Chad Tang; Russell K Pachynski; Robert Chin; Ravindra Majeti; Irving L Weissman
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

Review 6.  Programmed cell removal: a new obstacle in the road to developing cancer.

Authors:  Mark P Chao; Ravindra Majeti; Irving L Weissman
Journal:  Nat Rev Cancer       Date:  2011-12-08       Impact factor: 60.716

7.  The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.

Authors:  Stephen B Willingham; Jens-Peter Volkmer; Andrew J Gentles; Debashis Sahoo; Piero Dalerba; Siddhartha S Mitra; Jian Wang; Humberto Contreras-Trujillo; Robin Martin; Justin D Cohen; Patricia Lovelace; Ferenc A Scheeren; Mark P Chao; Kipp Weiskopf; Chad Tang; Anne Kathrin Volkmer; Tejaswitha J Naik; Theresa A Storm; Adriane R Mosley; Badreddin Edris; Seraina M Schmid; Chris K Sun; Mei-Sze Chua; Oihana Murillo; Pradeep Rajendran; Adriel C Cha; Robert K Chin; Dongkyoon Kim; Maddalena Adorno; Tal Raveh; Diane Tseng; Siddhartha Jaiswal; Per Øyvind Enger; Gary K Steinberg; Gordon Li; Samuel K So; Ravindra Majeti; Griffith R Harsh; Matt van de Rijn; Nelson N H Teng; John B Sunwoo; Ash A Alizadeh; Michael F Clarke; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-26       Impact factor: 11.205

8.  Signaling by Toll-like receptors 8 and 9 requires Bruton's tyrosine kinase.

Authors:  Sarah L Doyle; Caroline A Jefferies; Con Feighery; Luke A J O'Neill
Journal:  J Biol Chem       Date:  2007-10-11       Impact factor: 5.157

9.  C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells.

Authors:  C A Ogden; A deCathelineau; P R Hoffmann; D Bratton; B Ghebrehiwet; V A Fadok; P M Henson
Journal:  J Exp Med       Date:  2001-09-17       Impact factor: 14.307

10.  Disruption of SIRPα signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts.

Authors:  Alexandre P A Theocharides; Liqing Jin; Po-Yan Cheng; Tatiana K Prasolava; Andrei V Malko; Jenny M Ho; Armando G Poeppl; Nico van Rooijen; Mark D Minden; Jayne S Danska; John E Dick; Jean C Y Wang
Journal:  J Exp Med       Date:  2012-09-03       Impact factor: 14.307

View more
  105 in total

1.  Resolvin D1 promotes the targeting and clearance of necroptotic cells.

Authors:  Brennan D Gerlach; Michael Marinello; Justin Heinz; Nicholas Rymut; Brian E Sansbury; Colin O Riley; Sudeshna Sadhu; Zeinab Hosseini; Yoko Kojima; Dale D Tang; Nicholas J Leeper; Matthew Spite; Margarida Barroso; Katey J Rayner; Gabrielle Fredman
Journal:  Cell Death Differ       Date:  2019-06-20       Impact factor: 15.828

Review 2.  Cellular determinants and therapeutic implications of inflammation in pancreatic cancer.

Authors:  Meredith L Stone; Gregory L Beatty
Journal:  Pharmacol Ther       Date:  2019-05-31       Impact factor: 12.310

3.  Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia.

Authors:  Elisa ten Hacken; Maria Gounari; Jaap Willem Back; Ekaterina Shimanovskaya; Lydia Scarfò; Ekaterina Kim; Jared Burks; Maurilio Ponzoni; Giuseppe Alvise Ramirez; William G Wierda; Zeev Estrov; Michael J Keating; Alessandra Ferrajoli; Kostas Stamatopoulos; Paolo Ghia; Jan A Burger
Journal:  Haematologica       Date:  2017-07-27       Impact factor: 9.941

4.  Targeting CD47: the achievements and concerns of current studies on cancer immunotherapy.

Authors:  Yuting Huang; Yuchi Ma; Peng Gao; Zhi Yao
Journal:  J Thorac Dis       Date:  2017-02       Impact factor: 2.895

5.  SIRPA-Inhibited, Marrow-Derived Macrophages Engorge, Accumulate, and Differentiate in Antibody-Targeted Regression of Solid Tumors.

Authors:  Cory M Alvey; Kyle R Spinler; Jerome Irianto; Charlotte R Pfeifer; Brandon Hayes; Yuntao Xia; Sangkyun Cho; P C P Dave Dingal; Jake Hsu; Lucas Smith; Manu Tewari; Dennis E Discher
Journal:  Curr Biol       Date:  2017-06-29       Impact factor: 10.834

6.  Inhibition of EZH2 methyltransferase decreases immunoediting of mesothelioma cells by autologous macrophages through a PD-1-dependent mechanism.

Authors:  Malik Hamaidia; Hélène Gazon; Clotilde Hoyos; Gabriela Brunsting Hoffmann; Renaud Louis; Bernard Duysinx; Luc Willems
Journal:  JCI Insight       Date:  2019-09-19

7.  Dysregulated integrin αVβ3 and CD47 signaling promotes joint inflammation, cartilage breakdown, and progression of osteoarthritis.

Authors:  Qian Wang; Kazuhiro Onuma; Changhao Liu; Heidi Wong; Michelle S Bloom; Eileen E Elliott; Richard Rl Cao; Nick Hu; Nithya Lingampalli; Orr Sharpe; Xiaoyan Zhao; Dong Hyun Sohn; Christin M Lepus; Jeremy Sokolove; Rong Mao; Cecilia T Cisar; Harini Raghu; Constance R Chu; Nicholas J Giori; Stephen B Willingham; Susan S Prohaska; Zhen Cheng; Irving L Weissman; William H Robinson
Journal:  JCI Insight       Date:  2019-09-19

Review 8.  Macrophages: Key orchestrators of a tumor microenvironment defined by therapeutic resistance.

Authors:  Kristen B Long; Arthur I Collier; Gregory L Beatty
Journal:  Mol Immunol       Date:  2017-12-19       Impact factor: 4.407

9.  Cd47-Sirpα interaction and IL-10 constrain inflammation-induced macrophage phagocytosis of healthy self-cells.

Authors:  Zhen Bian; Lei Shi; Ya-Lan Guo; Zhiyuan Lv; Cong Tang; Shuo Niu; Alexandra Tremblay; Mahathi Venkataramani; Courtney Culpepper; Limin Li; Zhen Zhou; Ahmed Mansour; Yongliang Zhang; Andrew Gewirtz; Koby Kidder; Ke Zen; Yuan Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-30       Impact factor: 11.205

Review 10.  Combination cancer immunotherapies tailored to the tumour microenvironment.

Authors:  Mark J Smyth; Shin Foong Ngiow; Antoni Ribas; Michele W L Teng
Journal:  Nat Rev Clin Oncol       Date:  2015-11-24       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.